Cellectar BioSciences Inc. reported its third quarter 2025 financial results and provided a corporate update. The company announced plans to submit a Conditional Marketing Approval application in Europe for iopofosine I 131 in refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026, following guidance from the Scientific Advice Working Party of the European Medicines Agency. Cellectar also plans to submit a New Drug Application to the U.S. FDA for accelerated approval of iopofosine I 131 for Waldenstrom's Macroglobulinemia once a confirmatory trial is underway, contingent on sufficient funding. During the quarter, the company initiated a Phase 1b study of CLR 125 for triple-negative breast cancer and received Rare Pediatric Drug Designation for iopofosine I 131 in inoperable relapsed/refractory pediatric high-grade glioma. Additionally, Cellectar's early-stage asset, CLR 225, completed IND-enabling studies after demonstrating anti-tumor activity in pancreatic cancer models.